NICE U-turn for Kisqali in breast cancer
NICE has recommended Novartis’ Kisqali just three months after its initial rejection.
Read More
Tag: everolimus
SMC approves funding for six new therapies on the NHS
The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
Read More
Novartis’ Afinitor Disperz wins new TSC-related approval
Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
Read More
NICE u-turn backs combo for kidney cancer
In a turnaround from its earlier position, the National Institute for Health and Care Excellence is now endorsing NHS funding for Eisai’s Kisplyx plus everolimus for kidney cancer.
Read More
NICE turns down kidney cancer drugs
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
Read More
NICE backs Afinitor, Sutent for neuroendocrine tumours
Novartis’ Afinitor and Pfizer’s Sutent have received backing from the National Institute for Health and Care Excellence as cost-effective treatment options for certain neuroendocrine tumours (NETs).
Read More
Novartis’ Afinitor gets NICE green light for kidney cancer
The National Institute for Health and Care Excellence has now published final guidelines backing routine NHS use of Novartis’ Afinitor in certain patients with advanced kidney cancer.
Read More
EC further expands use of Novartis’ Votubia
The European Commission has expanded the approved uses of Novartis’ Votubia to include adjunctive treatment of patients aged two years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex.
Read More
NICE recommends Novartis’ kidney cancer drug
Some patients with kidney cancer should soon be able to get easier access to Novartis’ Afinitor on the NHS, after cost regulators backed moving the drug out of the Cancer Drug’s Fund and into the routine care pathway
Read More
NICE shoots down two CDF drugs
Patients with breast cancer and mantle cell lymphoma living in England and Wales have been dealt a blow after cost regulators rejected two drugs currently available through the Cancer Drugs Fund for routine NHS use.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
